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Abstract: - Considering the therapeutic aspects of thyrotoxicosis, 980 cases were studied, where 
probable role of stress in the etiopathogenesis has been explored. These cases were then treated 
with standard modern therapy containing antithyroid drug with a tranquilizer and some of the 
patients were treated only by an Ayurvedic drug. i. e. Sankhapuspi. In early cases Sankhapuspi 
was found more effective than standard modern treatment.  In addition, no side effect was noted 
in these patients treated with Sankhapuspi. 
Introduction 
For years, clinicians, particularly 
endocrinologists and psychiatrists have 
related  thyrotoxicosis with various 
psychological and emotional factors, which 
are considered as an important factor in the 
precipitatino for the development of this 
disease.  
1 ,
 2 & 
3 .  However, these cases are 
being treated throughout the world with the 
known antithyroid drug i.e. Neomercazole 
or Thiouracil.  Since the emotional factor is 
also considered as a causative factor, they 
were also given tranquilizer, in addition to 
antithyroid drug.  Such treatment has to be 
continued for years together with or without 
much improvement.  Sometimes they have 
to depend entirely on such regime of 
medical treatment throughout their life and 
some of them have to undergo surgical 
removal of  the gland. These procedures 
sometimes may produce toxic 
manifestations, 
4  or in due course of time 
failed to control the disease. 
Considering certain drawbacks in modern 
therapy, a thorough search for some 
indigenous drugs was made in the 
Ayurvedic literature. In this context, Caraka 
has mentioned the specific property of 
Sankhapuspi as brain tonic (Medhya C. Ch. 
1/30), whereas, other author have indicated 
its rasayana like properties, hypotensive 
activity 
5  and tranquilizing action.  
6,
  7 in 
addition to this tranquilizing activity, few 
workers have reported that Sankhapuspi also 
potentiates barbiturate hyponisis.  
7 & 
8 In 
this study, clinical data have been collected 
to indicate the probale mode of action of 
Sankhapuspi by using various modern 
parameters. 
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Materials and Methods 
In the present study, the trial of the 
Sankhapuspi was done in clinical cases of 
thyrotoxicosis having definite history of 
emotional stress. 
In this study, we have included 980 cases of 
thyrotoxicosis attending Thyroid clinic of S. 
S. Hospital of H. H. U. from 1965 to 1978. 
Out of these, 160 cases were selected for 
study and were divided into the following 
three groups. 
In addition to the history of emotional or 
Psychological stress, the various 
symptomatology of thyrotoxicosis were 
recorded.  After the diagnosis was 
confirmed, the patients were subjected to 
thyroid function tests including I 
131 uptake, 
serum PBI serum cholesterol ad T Resin 
uptake estimation.  Apart from this, their 
blood were also subjected to different 
biochemical investigations, i. e. 
acetylcholine, histamine, catecholamines, 
histraminase, cholinesterase, MAO and 5-
HT as per standard methods (Table-1). 
In the first group 100 cases of either sex 
were treated with a known anti-thyroid drug 
i.e. Neomercazole in the dose of 15 mg daily 
along with a tranquilizer i.e. Diazepam 5mg 
twice a day.  The second group of patients 
(30) was with Sankhapuspi syrup in the dose 
of 125gm twice daily, whereas third group 
of thirty patients was treated with combined 
therapy i.e. Sankhapuspi and Neomercazole 
in the same dose as mentioned below; 
Group No.  Total No. of Cases  Treatment  Dosage 
First Group  100  Neomercazole + Tranquilizer  15gm daily + 5mg B. D.  
Second Group  30  Sankhapuspi syrup alone  125gm. B. D. 
Third Group  30 
Sankhapuspi syrup                  
+ Neomercazole 
125mg B.D.  +                 
5gm T. D. S. 
 
Follow-up 
All the patients of each group were re-
examined at one month interval.  These 
patients were treated with different drugs up 
to 9 months of the duration.  At the time of 
follow-up, the efficacy of the drug was 
evaluated on clinical symptomatology and 
various laboratory investigations. 
RESULTS 
Effect of Neomercazole and Tranquilizer  
Those patients who were kept in this group 
were treated for 9 months with the 
combination of Neomercazole and 
Tranquilizer (Diazepam) in the dose of 5mg 
three times and 5mg twice a day 
respectively.  The percentage of 
improvement in their clinical features 
showed maximum improvement in this 
group of patients.  Clinical features like 
tachycardia, weakness and easily 
fatiguability were improved by 90% and 
neck swelling showed 60% improvement. 
Los in body weight, nervousness and pages 49-57 
appetite showed 80-83% improvement, 
whereas tremors and insomnia were 
improved by 76.6%.  The recovery in this 
group of patients was found maximum in 
comparison to the next group (Table-2). 
In addition the improvement of the clinical 
features and the result of the biochemical 
investigations showed a marked 
improvement and this could be co-related 
with the clinical symptomatology.  The 
thyroid function tests revealed a significant 
decrease in the I 
131 uptake 3 months after 
treatment value i.e. 42.4% in comparison to 
pre-treatment value i.e. 63.55%.  Similarly, 
serum PBI level which was raised before 
treatment i.e. 10.83/ug% had reduced to 
7.6/ug% and T
3  resin uptake also came 
down from 58.0% of its pre-treatment value 
to 42.5%.  On the other hand serum 
cholesterol level had increased to 180mg% 
from their pre-treatment value of 
140.40mg%.    The other biochemical 
investigations, like acetylcholine and total 
catecholamine showed a remarkable fall in 
the contents from 2.16 to 1.68/ug/ml. 
However, the value does not obtain the 
normal level i.e. 1.11/ug/ml by the end of 3 
months of the treatment (table-3). 
Effect of Sankhapuspi (Convolvulus 
pluricaulis) 
Patients who were treated only with 
Sankhapuspi syrup in the same dose and up 
to the same period showed almost similar 
percentage of improvement in the clinical 
features as observed in those patients who 
were treated with the combination 
Neomercazole and diazepam,.  The 
maximum percentage of improvement (90-
93%) was observed in clinical features like 
weakness, palpitation, nervousness and 
appetite whereas tachycardia tremors and 
easy fatiguability were found improved by 
82.86%.  The improvement in the neck 
swelling also observed nearly in the same 
percentage i.e. 56.6% as observed in group 
1. 73.3% of improvement was noticed in 
reduction in body weight  and insomnia 
(table-2) 
The thyroid function studies in this group of 
patients revealed a low I 
131  uptake i.e. 
40.6% and serum PBI level i.e. 5.60/ug%.  
There was a slight reduction in T3  resin 
uptake up to 43.8% from its pre-treatment 
value of 58.0%. However, the values 
remained higher in comparison to the 
normal va;ie pf 29.7%. On the other hand, 
the serum cholesterol level was found 
increased to 180.7mg% from its pre-
treatment value of 140.40mg%.  The most 
significant observation was a reduction in 
acetylcholine content i.e. 0.676/ug/ml in 
comparison to the remaining treated group.  
There was a little reduction in the total 
catecholamines level i.e. 21.0 ug/ml in 
camparison to the normal and pre-treatment 
value.  However, the reduction in 
catecholamines level was not statistically 
significant (Table-3). 
Effect of Sankhapuspi and Neomercasole 
Those patients were treated with 
Sankhapuspi along with Neomercazole, 
showed maximum improvement only in 
reduction in the neck swelling i.e. 66.6%.  
However, the rest of the clinical features 
showed a maximum improvement.  The 
percentage of improvement I the clinical 
symptomatology varied between 43 to 63% 
(Table-2). pages 49-57 
On laboratory investigations, it has been 
observed that I 
131 uptake was higher than 
Sankhapuspi treated group, but was lesser 
than the control value, whereas serum PBI 
was found much higher (8.6/ug%). The 
serum  cholesterol level did not show any 
difference between treated and conrol 
groups.  At the same time, there was a 
significant fall in the acetylcholine 
(i.e.0.765/ug/ml) from the control value 
(2.16/ug/ml). However, the level remained 
higher from those patients who were treated 
with Sankhapuspi alone i.e. 0.676/ug/ml. On 
the other hand, no difference could be 
observed in catecholamine level in 
comparison to the control and normal values 
(Table-3). 
Discussion 
In spite of considerable ignorance regarding 
the  etio-pathogenesis of thyrotoxicosis, 
much has been known about its treatment.  
The antithyroid drug, which was introduced 
first by Astwood in 1940
10,  was found 
effective by controlling the synthesis of 
thyroid hormone.  This was probably 
through interference either with the organic 
blinding of the Iodine or with the trapping of 
the small amount of Iodine circulating in the 
blood by the gland.  The other advantage of 
antithyroid drug (Neomercazole) is that it is 
suitable for children, young, adults, pregnant 
women, and in patients with mild 
occurrence of the disease.  The mode of 
mechanism of action of antithyroid drugs is 
a well known phenomenon. However, these 
drugs are considered to exert their action 
mainly by inhibiting the oxidation, organic 
binding of thyroidal iodine and the coupling 
of iodotyrosines primarily, and the 
formation of DIT and MIT secondarily.  
11 
The main disadvantage of such antithyroid 
drugs is that the treatment has to be 
continued for longer period.  Furthermore, 
the recurrence of the  disease with certain 
toxic manifestations like skin rashes, drug 
fever, agranulocytosis are also reported.   
Most of the workers in this field have used 
Neomercazole in the dose of 10mg three to 
four times a day.  However, in the present 
series Neomercazole was administered 5mg 
three times a day which showed fairly good 
response excepting tachycardia’ 
exophthalmos and neck swelling.  The other 
clinical features did not improve much with 
this treatment.  Similarly, badrcnergic 
blocking agents have also been used with 
considerable success in the symptomatic 
treatment of thyrotoxicosis. 
12,13  This drug 
mainly control the tachycardia and tremors 
to a considerable extent, these observations 
tend to suggest that the administration of 
antithyroid drugs alone does not control the 
disease. As mentioned earlier, in the present 
study majority of the cases of the toxicosis 
had psychosocial stress prior to the 
development of the disease.  Therefore, 
some of the patients, were treated with the 
combination of antithyroid drug 
(Neomercazole) and a tranquilizer 
(Diazepam).  The patients, treated with 
above combined therapy showed maximum 
improvement in almost all the clinical 
features.  The observations indicate that the 
administration of antithyroid drug in lower 
dose along with diazepam is more beneficial 
and effective with less chances of recurrence 
than  Neomercazole alone in higher dose.  
However, as mentioned earlier, the medical 
treatment still has to be continued for years pages 49-57 
together.  Under the circumstances it is quite 
possible that longer use of antithyroid drug 
may produce its toxic symptoms.
4 
Considering the above mentioned draw 
backs in modern antithyroid drug, a 
thorough, search for some indigenous drugs 
was made in the ancient Indian medical 
classics.  Accordingly, one of the herbal 
drugs i.e. Sankhapuspi (C. pluricaulis Chois) 
was selected for the purpose. Many workers 
have shown that Sankhapuspi (C. pluricaulis 
Chois) possess tranquilizing properties and 
potentiates barbiturate hypnosis 
7,
  8  The 
result of this study revealed maximum 
improvement in the clinical features in cases 
treated  with Sankhapuspi.  The 
symptomatic improvement, however was 
reduced when this indigenous drug was 
combined with antithyroid drug i.e. 
Neomercazole.  At the same time, the 
thyroid function tests showed significant 
reduction in serum PBI level in patients who 
were treated with Sankhapuspi alone or in 
the combination with antithyroid drug as 
compared to diazepam with Neomercazole 
treated group.  A very little difference could 
be seen in I 
131 uptake in any one of the 
treated groups.  However I 
131 uptake was 
lowest in Sankhapuspi treated and also in 
Neomercazole and diazepam treated groups.  
This indicates that Sankhapuspi has 
tranquilizing effect in addition to antithyroid 
property.  As a result of it, this indigenous 
drug considerably improves the clinical 
features of thyrotoxicosis .  It was 
interesting to note, that in spite of reduction 
in thyroid activity, no appreciable 
improvement could be observed in the 
clinical features when this drug was given in 
combination with an antithyroid drug.  It is 
known that the antithyroid drug acts by 
interaction of iodine with sulphydryl 
grouping resulting into the formation of 
disulphide. 
10 Hence, it is quite possible that 
the thiol grouping of Neomercazole might 
be reacting with some chemical compound 
incorporated in the Sankhapuspi syrup and 
this might be a factor for reducing the 
activity of this drug when used in 
combination as reflected in the clinical 
findings.  Thus, it indicates that this drug 
should not be administered at the same time.  
However following treatment with 
Sankhapuspi alone, circulating acetylcholine 
levels were reduced in thyrotoxic subjects as 
compared to those treated with diazepam 
alone.  A similar observation was observed 
in those patients who were treated with 
combined therapy.  There was not much 
difference in plasma catecholamine level in 
all the treated groups except a little decrease 
in Shankhapuspi treated patients.  These 
observations confirm previous finding that 
Sankhapuspi possesses powerful 
tranquilizing of effect specifically by 
reducing the acetylcholine content n the 
blood.  This decrease in the acetylcholine 
content in the blood might be due to 
accumulation of this substance in the brain 
tissue.  Further it also indicates that this drug 
dose not affect the adrenomedullary activity 
as evident by unchanged catecholamine 
levels. 
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Table – 1 
METHODS OF BIOCHEMICAL INVESTIGATIONS 
Investigations  Methods  References 
I 
131 uptake  Hamilton and Soley, 1939  Proc. Nat. Acad. Sc. 26: 483,1939 
Serum PBI  Acland, 1957  Biochem. J. 66: 177, 1957 
Serum Cholesterol  Bloor. W. R. 1923  J. Biol. Chem. 56: 711, 1923 
T3 Resin uptake  Clark, F. 1963  Lancet 2: 167, 1963 
Acetylcholine   Pandey and Udupa et al., 1975  Ind. J. Expti. Biol. 13:327, 1975 
Histamine  (iark et al., 1960.  Edited Blick, D, VOl. 111. Intersciences Publishers 1960 
Catecholamines  Griffiths et al, 1970  Clin. Chem, Acta 30:395, 1970 
Histaminase  Arsen and Kemp, 1964.  Nature (London) 204:1195, 1964 
Cholinesterase  Caraway’s Spectrophotometric  Am J Clin Pathology 26:945, 1956 
MAO  Charle’s and McEwen, 1971  Methods in Enzymology, Vol XVII B, 692 (1971) Edited by 
Herbert Tabor & Cliwhite Tabur, Academic press, New York. 
5-HT  Snyder et al., 1965  Biochem Pharmacol 14:831, 1965 
Catecholamines (Tissue)  Grout. 1961  Standard Methods of Clin. Chemistry. Edited by Saligson, 
Academic press, N Y, Vol. 3, P. 62, 1961. 
DBH  Nagatsu, T. and Udenfriend, S. 1972  Clin. Chem. 18:9, 1972. 
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Table – 2 
PERCENTAGE OF IMPROVEMENT IN CLINICAL FEATURES 
       
Clinical Features  Neomercazole + Tranquilizer  Sankhapuspi Syrup  Sankhapuspi + Neomercazole 
       
Tachycardia  90.0  80.0  63.3 
Tremors  76.6  83.3  56.6 
Weakness  90.0  90.0  56.6 
Neck Swelling  60.0  56.6  66.6 
Palpitation  76.6  90.0  56.6 
Easily Fatiguability  90.0  86.6  56.6 
Reduction in body weight  80.0  73.3  46.6 
Nervousness  83.3  93.3  56.6 
Increased appetite  83.3  90.2  50.0 
Insominia  76.6  73.3  43.3 
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Table – 3 
BIOCHEMICAL INVESTIGATIONS (VALUES MEAN ± S. D.) 
             
Groups  Therapy  RAI%  PBI/ug%  Serum Cholesterol 
mg% 
Acetylcholine/
ug/ml 
Total catecholomines/ 
ug/ml 
 
             
One  Neomercazole + 
Diazepam 
42.5
1 ± 1.4  7.6 
1 ± 1.01  180.0
3 ± 5.7  1.68
2 ± 0.51  27.58
2 ± 3.14 
 
Two  Sankhapuspi  40.6
1 ± 1.4
  5.60
1 ± 1.78  180.7 
2 ± 57.21  0.678
1 ± 0.085  21.0
2 ± 3.24 
 
Three  Sankhapuspi 
Neomercazole 
50.5
2 ± 1.20  8.6
2 ± 2.0
  148.9
2 ±19.87  0.795
1 ± 0.264  26.24
2 ± 0.669 
 
Control Values 
(stress) 
-    63.55
1 ± 12.17  10.83
4 ± 1.13
  14.40
2 ± 30.90  2.16
1  ± 0.54  30.1
2 ± 9.48 
 
Normal values  -    35.0 ± 10.0  6.2 ± 1.2  175.5 ± 20.23  1.11 ± 0.12  26.1 ± 5.4 
 
 
1 p<0.05    (as compared with normal values) 
2 p<0.025  (as compared with normal values) 
3 p<0.01    (as compared with normal values) 
4 <0.001    (as compared with normal values) pages 49-57 
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